UroGen Pharma URGN Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- UroGen Pharma (URGN) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $4.15M in Q1 2026.
- How has UroGen Pharma's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
- UroGen Pharma's proceeds from maturities, prepayments and calls of debt securities, available-for-sale decreased by 89.7% year-over-year, from $40.43M to $4.15M.
- What is the long-term trend for UroGen Pharma's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
- Over 4 years (2021 to 2025), UroGen Pharma's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a 26.6% compound annual growth rate (CAGR), from $54.26M to $139.25M.
- What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
- This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.